US · Healthcare · Biotechnology
EPS came in at -0.43 against a street estimate of -0.49 — a beat of 12.2%.
Analysts rate Acrivon Therapeutics, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $11.50.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 28.54% |
| Sands Capital Ventures, LLC | 5.34% |
| Acadian Asset Management LLC | 2.72% |
| Vanguard Capital Management, LLC | 2.22% |
| Wellington Management Company LLP | 2.07% |
| Renaissance Technologies Corp | 1.77% |
| Two Sigma Investments LLC | 1.50% |
| Marshall Wace Asset Management Ltd | 1.24% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Acrivon Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.